UNSPSC 51292606: Clorazepate dipotassium

This classification denotes a benzodiazepine with the molecular formula C16H10ClN2O3.2K.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63FN7G03XY, chemically known as 7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1h-1,4-benzodiazepine-3-carboxylic acid but more generally known as clorazepate dipotassium, which bears US NIH Compound Identifier 2809. European Medicines Agency schedules Clorazepate dipotassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13397MIG.

UNSPSC 51292606 Clorazepate dipotassium is a Commodity code that nominally specifies a single benzodiazepine pharmaceutical product, yet the recent state and local solicitations tagged to this code show little activity directly aligned with clorazepate procurement. Instead, the opportunities reveal purchasing of broader pharmaceutical categories — naloxone and drug deactivation systems for community health, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and exploratory vendor engagement for direct-to-manufacturer prescription programs. State and local governments issuing under this code span county health systems (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). The issuing bodies reflect a mix of health department procurement and cooperative purchasing consortia that consolidate demand across jurisdictions.

Recent activity shows geographic spread across Florida, Texas, and the Upper Midwest through the MMCAP vehicle. Representative solicitations include Seminole County's IFB60459723LAS (posted June 30, 2026; due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery with E-Verify and drug-free workplace compliance; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment capabilities outside traditional PBM and GPO channels; and MMCAP's RFP S1070000015802 (posted January 20, 2026; responses due March 26, 2026) establishing multi-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers with pricing evaluation weighted 75 percent on competitiveness and 10 percent on fixed pricing. The code shows minimal relevant recent activity for clorazepate specifically; the tagged opportunities address pharmaceutical procurement broadly rather than this single product line.